PMID- 17507828 OWN - NLM STAT- MEDLINE DCOM- 20070802 LR - 20070702 IS - 0023-852X (Print) IS - 0023-852X (Linking) VI - 117 IP - 7 DP - 2007 Jul TI - A novel drug therapy for recurrent laryngeal nerve injury using T-588. PG - 1313-8 AB - OBJECTIVES/HYPOTHESIS: We have previously shown that gene therapy using Insulin-like growth factor (IGF)-I, glial cell line-derived neurotrophic factor (GDNF), and brain-derived neurotrophic factor (BDNF), or a combination of these trophic factors, is a treatment option for recurrent laryngeal nerve (RLN) palsy. However, there remain some difficulties preventing this option from becoming a common clinical therapy for RLN injury. Thus, we need to develop novel treatment option that overcomes the problems of gene therapy.R(-)-1-(benzothiophen-5-yl)-2-[2-N,N-diethylamino]ethoxy]ethanol hydrochloride (T-588), a synthetic compound, is known to have neuroprotective effects on neural cells. In the present study, the possibility of new drug treatments using T-588 for RLN injury was assessed using rat models. STUDY DESIGN: Animal study. METHODS: Animals were administered T-588 for 4 weeks. The neuroprotective effects of T-588 administration after vagal nerve avulsion and neurofunctional recovery after recurrent laryngeal nerve crush were studied using motoneuron cell counting, evaluation of choline acetyltransferase immunoreactivity, the electrophysiologic examination, and the re-mobilization of the vocal fold. RESULTS: T-588 administration successfully prevented motoneuron loss and ameliorated the choline acetyltransferase immunoreactivity in the ipsilateral nucleus ambiguus after vagal nerve avulsion. Significant improvements of motor nerve conduction velocity of the RLN and vocal fold movement were observed in the treatment group when compared to controls. CONCLUSION: These results indicate that oral administration of T-588 might be a promising therapeutic option in treating peripheral nerve injury. FAU - Mori, Yuko AU - Mori Y AD - Department of Otolaryngology-Head and Neck Surgery, Keio University School of Medicine, Shinjuku, Tokyo, Japan. FAU - Shiotani, Akihiro AU - Shiotani A FAU - Saito, Koichiro AU - Saito K FAU - Araki, Koji AU - Araki K FAU - Ikeda, Ken AU - Ikeda K FAU - Nakagawa, Masaya AU - Nakagawa M FAU - Watabe, Kazuhiko AU - Watabe K FAU - Ogawa, Kaoru AU - Ogawa K LA - eng PT - Journal Article PL - United States TA - Laryngoscope JT - The Laryngoscope JID - 8607378 RN - 0 (Diethylamines) RN - 0 (Neuroprotective Agents) RN - 0 (Thiophenes) RN - 142935-03-3 (T 588) SB - IM MH - Animals MH - Diethylamines/pharmacology/*therapeutic use MH - Electromyography MH - Laryngeal Muscles/drug effects/innervation MH - Male MH - Motor Neurons/drug effects/pathology MH - Neuroprotective Agents/pharmacology/*therapeutic use MH - Rats MH - Rats, Sprague-Dawley MH - Thiophenes/pharmacology/*therapeutic use MH - Treatment Outcome MH - Vocal Cord Paralysis/*drug therapy/*pathology EDAT- 2007/05/18 09:00 MHDA- 2007/08/03 09:00 CRDT- 2007/05/18 09:00 PHST- 2007/05/18 09:00 [pubmed] PHST- 2007/08/03 09:00 [medline] PHST- 2007/05/18 09:00 [entrez] AID - 10.1097/MLG.0b013e31805f681f [doi] PST - ppublish SO - Laryngoscope. 2007 Jul;117(7):1313-8. doi: 10.1097/MLG.0b013e31805f681f.